September 2022 Top Biopharma Deal: SpringWorks – GSK for Nirogacestat in combination with Blenrep

Oct 5, 2022 | Deal of the Month, Partnership Deals

September 2022 Top Biopharma Deal Upfront
SpringWorks development and commercialization deal expansion with GSK for Nirogacestat in combination with Blenrep (expanded deal)

Highlighted Deal Financial Comps

Date Announced:

September 7, 2022

Total Deal Value:

$625M

Upfront Cash:

n/a

Upfront Equity:

$75M

Option Payments:

n/a

Total Milestones:

$550M dev. and commercial milestones

Royalties:

Undisclosed

Cost & Profit Split:

m/a

Deal Synopsis

The Asset:

Springworks’ Nirogacestat, an oral gamma-secretase inhibitor, in combination with GSK’s Blenrep, an antibody-drug conjugate targeting B-cell maturation antigen for the treatment of multiple myeloma.

Deal Structure:

Development and Commercial License

Partnership Features:

Collaborative Development, No Shared Cost; Co-Development, Shared Dev Cost

Deal Details:

  • SpringWorks expanded its 2019 clinical collaboration and granted GSK non-exclusive rights to develop and commercialize its nirogacestat, an oral gamma-secretase inhibitor, in combination with GSK’s Blenrep, an antibody-drug conjugate targeting B-cell maturation antigen for the treatment of multiple myeloma.
  • SpringWorks retains full commercial rights to nirogacestat and will be responsible for the global commercialization of nirogacestat.
  • SpringWorks will receive a $75M equity investment in shares of common stock at a premium to the 30-day volume-weighted average share price on Sept 2, 2022, and is eligible to receive up to $550M in development and commercial milestones.

Last Month:

Congrats to SpringWorks and GSK for landing DealForma’s September 2022 Top Biopharma Deal. Last month’s Deal of the Month was Sanofi – Innovent for antibody-conjugate drug SAR408701 for the treatment of non-small cell lung cancer (NSCLC). Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

20,378

Licensing Deals

17,730

Funding Rounds

4,034

M&A

31,012

Company Profiles

5,478

Other Deals

26,505

Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Introducing: DealForma plus Tableau

Introducing: DealForma plus Tableau

We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...

Venture & IPO – Medtech – Q1 2023 

Venture & IPO – Medtech – Q1 2023 

The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...